PLUS1
6.59
0.09 (1.38%)
0.09 (1.38%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Immunic Inc | IMUX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.41 | 6.73% | 6.50 | 6.0213 | 7.00 | 6.09 | 6.09 | 20:00:00 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 4.50 | 9.94 | 5.44 | 54.73% | 2 | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 270 | 25,460 | $ 6.45 | $ 164,194 | 26,648 | 4.19 - 22.6626 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:00:00 | 8 | $ 6.59 | USD |
Immunic Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 69.84M | 10.74M | $ -41.48M | -11.70 | - | 10.41M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | 1.00 | 3.10% |
Immunic News
| Date | Time | Source | News Article |
|---|---|---|---|
| 4/09/2020 | 10:34 | Edgar (US Regulatory) | Other Filing |
| 4/09/2020 | 10:34 | Edgar (US Regulatory) | Other Filing |
| 3/23/2020 | 10:09 | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) |
| 3/16/2020 | 16:09 | Edgar (US Regulatory) | Annual Report (10-k) |
| 3/16/2020 | 16:09 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 3/16/2020 | 16:01 | PR Newswire (US) | Immunic, Inc. Reports Year End 2019 Financial Results and.. |
| 2/11/2020 | 06:30 | PR Newswire (US) | Immunic, Inc. to Participate in Scientific and Investor.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IMUX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 5.57 | 7.20 | 5.28 | 6.38 | 25,066 | 0.93 | 16.7% |
| 1 Month | 7.00 | 10.00 | 4.19 | 6.61 | 44,748 | -0.50 | -7.14% |
| 3 Months | 9.49 | 10.00 | 4.19 | 7.40 | 26,417 | -2.99 | -31.51% |
| 6 Months | 9.55 | 10.00 | 4.19 | 7.96 | 27,940 | -3.05 | -31.94% |
| 1 Year | 22.00 | 22.6626 | 4.19 | 12.63 | 68,378 | -15.50 | -70.45% |
| 3 Years | 22.00 | 22.6626 | 4.19 | 12.63 | 68,378 | -15.50 | -70.45% |
| 5 Years | 22.00 | 22.6626 | 4.19 | 12.63 | 68,378 | -15.50 | -70.45% |
Immunic Description
| Immunic Inc is a clinical stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing remitting multiple sclerosis, and psoriasis. The company is developing three small molecule products, IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH, IMU-935 is an inverse agonist of RORyt and IMU-856 targets the restoration of the intestinal barrier function. |
